INO-5401

INO-5401 is a cancer vaccine developed by Inovio Pharmaceuticals. Its target is PSMA (the sponsor names WT1, PSMA, hTERT). The sponsor states: A combination of three separate DNA plasmids targeting the Wilms tumour gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT), delivered intramuscularly followed by electroporation with the CELLECTRA device to stimulate an anti-tumour immune response. ClinicalTrials.gov describes the intervention as: INO-5401 is a combination of 3 separate DNA plasmids targeting Wilms tumour gene-1 (WT1) antigen, prostate-specific membrane antigen (PSMA) and human telomerase reverse transcriptase (hTERT) genes. Starting on Day 0 three milligrams (mg) of. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in glioma & glioblastoma. The largest, NCT03491683, plans to enrol 52 participants (actual) with primary completion expected 2026-12-31. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.